Robert A Kitchen

US Patent:

20200292561, Sep 17, 2020

Filed:

Jul 12, 2018

Appl. No.:

16/629000

Inventors:

- Waltham MA, US
Erez EITAN - Waltham MA, US
Christine COTICCHIA - Waltham MA, US
Johan Karl Olov SKOG - Lincoln MA, US
Robert KITCHEN - Somerville MA, US
Seth YU - Waltham MA, US

Assignee:

Exosome Diagnostics, Inc. - Waltham MA

International Classification:

G01N 33/68
C12N 15/10
G01N 33/537

Abstract:

The invention relates generally to a process for isolating subpopulations of EVs to identify biomarkers useful identifying, determining the progression of, and/or prognosing a disease, including a neurological disease. More particularly, the present invention relates to detection technology of various exosomal biomarkers including proteins, protein modifications, sugars, RNA, DNA, lipids, and metabolites, and combinations thereof.

US Patent:

20200208213, Jul 2, 2020

Filed:

Oct 23, 2017

Appl. No.:

16/342572

Inventors:

- Waltham MA, US
Sudipto CHAKRABORTTY - Waltham MA, US
Dalin CHAN - Brighton MA, US
Michael VALENTINO - Waltham MA, US
Vasisht TADIGOTLA - Newton MA, US
Robert KITCHEN - Somerville MA, US
Dominik GRIMM - Schondorf Am Ammersee, DE
Wei YU - Belmont MA, US

International Classification:

C12Q 1/6874
G01N 1/28
C12N 15/10
G01N 33/543

Abstract:

The invention provides a series of steps that prepare nucleic acids (RNA and/or DNA) isolated from extracellular vesicles for sequencing. This enables a wide diversity of RNAs and/or DNAs, to be efficiently detected. These can then be used to identify various attributes such as gene expression, alternative splicing, and the detection of both somatic and germline mutations including single nucleotide variants (SNV) and structural variations (insertions/deletions, fusions, inversions).

US Patent:

20200199675, Jun 25, 2020

Filed:

May 16, 2018

Appl. No.:

16/613298

Inventors:

- Waltham MA, US
- Boston MA, US
Robert KITCHEN - Somerville MA, US
Vasisht TADIGOTLA - Newton MA, US
Johan Karl Olov SKOG - Lincoln MA, US
Jamil AZZI - Boston MA, US

International Classification:

C12Q 1/6883
G01N 1/28
G01N 33/68

Abstract:

The invention relates generally to the use of microvesicle biomarkers such as nucleic acids, including nucleic acid signatures, and/or proteins for assessing a kidney transplant rejection in a patient. The invention further relates to assessing, and/or to monitoring kidney transplant rejection in patients who have received a renal transplant.